

# Nabumetone

Catalog No: tcsc2669



## Available Sizes

Size: 1g

Size: 5g

Size: 10g



## Specifications

**CAS No:**

42924-53-8

**Formula:**

$C_{15}H_{16}O_2$

**Pathway:**

Immunology/Inflammation

**Target:**

COX

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 100$  mg/mL (438.04 mM); H<sub>2</sub>O :

**Alternative Names:**

BRL14777

**Observed Molecular Weight:**

228.29


## Product Description

Nabumetone is an orally active non-acidic anti-inflammatory agent, acts as a potent and selective **COX-2** inhibitor, and is the prodrug of the active metabolite 6MNA.

IC50 & Target: COX-2<sup>[1]</sup>

**In Vitro:** Nabumetone is a potent and selective COX-2 inhibitor. Nabumetone (50  $\mu$ mol-2 mmol) dose-dependently inhibits the proliferation of K-562 and Meg-01 cells, but shows no obvious apoptotic effect. Nabumetone potentiates the apoptotic effect of ADR in the K-562 cell line. Moreover, Nabumetone reduces Bcl-2 expression<sup>[1]</sup>.

**In Vivo:** Nabumetone (79 mg/kg, p.o.) inhibits paw oedema and paw exudate PGE<sub>2</sub> in rats. Nabumetone does not induce gastric damage and causes only 57% inhibition of gastric mucosal 6-keto-PGF<sub>1 $\alpha$</sub>  production in rats<sup>[2]</sup>. Nabumetone (25, 50, 100 mg/kg, i.p.) dose-dependently inhibits the increase of DDC-induced mucus secretion and stimulates stress-induced mucus secretion in rats. Nabumetone (25 mg/kg, i.p.) significantly suppresses stress-induced ulcer index in rats<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!